EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Exploration of the benefits and resistance mechanisms of immunotherapy based on PD-L1 expression, circulating tumor DNA and T-cell receptor profiles in advanced gastric cancer

Miaomiao Gou, Niansong Qian, Yong Zhang, Bingfa Yan, Zhikuan Wang, Guanghai Dai

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04248-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Miaomiao Gou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Senior department of oncology, Chinese PLA General hospital, Dongda street 8, Fengtai District, Beijing, 100853, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, B7-H1 Antigen, Circulating Tumor DNA, Immunotherapy. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Combination regimens of immunotherapy and chemotherapy have become the standard treatment for HER2-negative advanced gastric cancer (AGC). Here, we evaluate the therapeutic efficacy of first-line treatment regimens across different PD-L1 expression, circulating tumor DNA (ctDNA) and T-cell receptor (TCR). METHODS: This study retrospectively recruited 245 patients with AGC. 55 blood samples from 20 patients were prospectively collected before immunotherapy, after two cycles of treatment, and during disease progression. RESULTS: In the CPS < 5 cohort, chemotherapy + PD-1 inhibitor + anti-angiogenic treatment showed a higher progression-free survival (PFS). In the CPS ≥ 5 cohort, chemotherapy + PD-1 inhibitor improved median PFS (p = 0.04) and ORR (p = 0.014) over chemotherapy alone. ctDNA analysis revealed that at various time points, patients in the short-PFS group exhibited significantly elevated maxVAF and ctDNA levels. Post-treatment, ctDNA levels decreased in 50% of patients in the long-PFS group, whereas only 25% in the short-PFS group. The short-PFS group had a lower TCR clone count, while no significantly different in the diversity of the TCR repertoire compared with long-PFS groups. CONCLUSIONS: These findings suggest the different efficacy of first-line treatment regimens across varying levels of PD-L1 expression, and the molecular characteristics of patients with long-term benefits from immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsB7-H1 AntigenCirculating Tumor DNAImmunotherapyReceptors, Antigen, T-CellDrug Resistance, NeoplasmHumansFemaleMaleMiddle AgedAgedRetrospective StudiesAdultBiomarkers, TumorImmune Checkpoint InhibitorsAged, 80 and overPrognosis

Stichwörter der Autor:innen

Circulating tumor DNAClinical applicationGastric cancerImmunotherapyT-cell receptor

Substanzen

B7-H1 AntigenCD274 protein, humanCirculating Tumor DNAReceptors, Antigen, T-CellBiomarkers, TumorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Senior department of oncology, Chinese PLA General hospital, Dongda street 8, Fengtai District, Beijing, 100853, China.
  • The Eighth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
  • Medical Oncology Department, the Second Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
  • Geneplus-Beijing Institute, Beijing, China.
  • State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
  • Senior department of oncology, Chinese PLA General hospital, Dongda street 8, Fengtai District, Beijing, 100853, China. daigh60@sohu.com.

Zitieren

APA

Gou, M., Qian, N., Zhang, Y., Yan, B., Wang, Z., & Dai, G. (2025). Exploration of the benefits and resistance mechanisms of immunotherapy based on PD-L1 expression, circulating tumor DNA and T-cell receptor profiles in advanced gastric cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04248-0

Vancouver

Gou M, Qian N, Zhang Y, Yan B, Wang Z, Dai G. Exploration of the benefits and resistance mechanisms of immunotherapy based on PD-L1 expression, circulating tumor DNA and T-cell receptor profiles in advanced gastric cancer. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04248-0

BibTeX
@article{Gou2025,
  author = {Gou, Miaomiao and Qian, Niansong and Zhang, Yong and Yan, Bingfa and Wang, Zhikuan and Dai, Guanghai},
  title = {Exploration of the benefits and resistance mechanisms of immunotherapy based on PD-L1 expression, circulating tumor DNA and T-cell receptor profiles in advanced gastric cancer},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04248-0}
}
Kostenlos starten →